I chatted with Lynn Schifano! Don't miss out on SANS #HolidayHack x @SANSInstitute sans.org/holidayhack

Great presentations & discussion of QOL & AEs for hormonal tx options w/ biochemical recurrence ⁦@SFreedlandMD⁩ ⁦@RonaldChenMD⁩ ⁦@Cpaller⁩. Bottom line is AEs differ substantially w/ single agent and combos approaches. Don’t give triple tx. ⁦@ASCO⁩ #asco24

Great to have #nursing involved with @Integrativeonc patient advocacy committee! @write4wellness @Cpaller

Comparing docetaxel + I.V. ascorbic acid in mCRPC @Cpaller @CaPsurvivorship @HopkinsMedicine #clinicaltrials bit.ly/2EldYIY

Our #qualitative approach to illuminate factors in missed #prostatecancer dx: ncbi.nlm.nih.gov/pubmed/28786124 @Cpaller @alan_partin @brady_urology

Muscadine grape skin in prostate cancer: who benefits? #GU17 @HopkinsMedicine

Biden asks oncologists to make clinical trials available to 96% of cancer patients who are not treated on studies. gumdroptrials.org

PD-1 blockade shrinks tumors with mismatch repair deficiency. Dung Le and Luis Diaz

E3805: …cer-matters.blogs.hopkinsmedicine.org/2014/03/13/hor…

ASCO update: Early chemotherapy for men with newly diagnosed extensive metastatic prostate cancer improves survival. nyti.ms/1kllhze

Enzalutamide prechemo:nejm.org/doi/full/10.10…

Importance of screening high risk men jwatch.org/na34512/2014/0…

jco.ascopubs.org/content/early/… (2/2)

In men with localized prostate cancer, a recent study found, primary androgen deprivation therapy should be reserved for high-risk patients.